Results 201 to 210 of about 101,617 (297)

Beyond glycemic control: the cardiac and hepatic benefits of SGLT2 and DPP-4 inhibitors in mitigating chronic cadmium-induced inflammation, oxidative/nitrative stress, apoptosis and fibrosis. [PDF]

Front Physiol
Hassan FE, Hassanien MM, Selmy A, Mahmoud LM, Darwish A, Aldreny BA.   +5 more
europepmc   +1 more source

DPP-4 Inhibitors as Antidiabetic Agents

Journal of Analytical & Bioanalytical Techniques, 2010
openaire   +1 more source

Drug‐Induced Sialolithiasis—A Big‐Data Retrospective Study

Oral Diseases, EarlyView.
ABSTRACT Background Sialolithiasis pathophysiology is multifactorial, with systemic medications often hypothesised as a key contributor, particularly in older adults (Drug‐Induced Sialolithiasis). However, robust evidence supporting this theory is limited.
Gal Avishai, Gil Caspi, Akhilanand Chaurasia, Gavriel Chaushu, Daya Masri, Ehud Jonas   +5 more
wiley   +1 more source

Cardiovascular Sequel in Type-2 Diabetes Mellitus Patients on Various Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systemic Review and Meta-Analysis. [PDF]

Cureus
Prakash V, Goel N.
europepmc   +1 more source

Recombinant LPG3 Protein From Leishmania chagasi as an Antigen for the Diagnosis of Canine Visceral Leishmaniasis

Tropical Medicine &International Health, EarlyView.
ABSTRACT Visceral leishmaniasis (VL) is a human neglected tropical disease in which dogs participate as reservoirs of the etiological agent Leishmania chagasi. The identification of infected dogs is important to the control of VL, and recombinant proteins are strong antigen candidates for canine visceral leishmaniasis (CVL) serodiagnosis. In this work,
Thaís Viana Fialho Martins, Anna Cláudia Alves de Souza, Bianca Meireles Miranda, Ronny Francisco de Souza, Daniel Silva Sena Bastos, Neverton José Silva Ferreira, Tiago Antônio de Oliveira Mendes, Celeste da Silva Freitas de Souza, George Luiz Lins Machado‐Coelho, Maria Terezinha Bahia, Leandro Licursi de Oliveira, Juliana Lopes Rangel Fietto, Eduardo de Almeida Marques‐da‐Silva   +12 more
wiley   +1 more source

Global research trends on DPP-4 inhibitors and cardiovascular outcomes: a comprehensive bibliometric analysis. [PDF]

Ann Med Surg (Lond)
Amini-Salehi E, Hasanpour M, Alotaibi A, Rashidian P, Hashemi SM, Nasrollahizadeh A, Letafatkar N, Saberian P, Amani-Beni R, Shanbehzadeh N.   +9 more
europepmc   +1 more source

Improvement of Glycemia by DPP-4 Inhibitors

Journal of the Japan Diabetes Society, 2013
Nishi, Y., Fujimoto, S.
openaire   +1 more source

Survodutide for the Treatment of Obesity Disease in Japanese Participants: Rationale, Design and Baseline Characteristics of the Phase 3 SYNCHRONIZE‐JP Trial

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 6595-6606, August 2026.
ABSTRACT Aims There is an unmet need for effective pharmacotherapy for obesity disease management in Japan. Survodutide is a novel glucagon receptor/glucagon‐like peptide‐1 receptor (GLP‐1R) dual agonist with the potential to induce greater weight reductions than GLP‐1R mono‐agonists. We report the design and baseline participant characteristics of the
Koutaro Yokote, Toshimasa Yamauchi, Yasushi Fukushima, Yoji Takatsuka, Marie Kato, Shijia Yan, Takayoshi Inoue, Luiza Borowska, Martina Brueckmann, Wataru Ogawa, on behalf of the SYNCHRONIZE‐JP Trial Investigators   +10 more
wiley   +1 more source

Association of DPP-4 inhibitors with respiratory and cardiovascular complications in patients with COPD: a nationwide cohort study. [PDF]

ERJ Open Res
Yen FS, Wei JC, Ko FS, Huang Y, Yip HT, Tsai FJ, Hwu CM, Hsu CC.   +7 more
europepmc   +1 more source

Insulin Sensitivity and Beta Cell Function With Macupatide Alone or With Dulaglutide in Type 2 Diabetes: A Phase 1b, Randomised Controlled Trial

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 7196-7206, August 2026.
ABSTRACT Aims This Phase 1b, randomised, double‐blind clinical trial investigated the contribution of glucose‐dependent insulinotropic polypeptide (GIP) and glucagon‐like peptide‐1 (GLP‐1) to insulin sensitivity and secretion in people with type 2 diabetes (T2D) on metformin. Materials and Methods Participants were randomised to receive the long‐acting
Tim Heise, Eric Zijlstra, Andrea Mari, William C. Roell, Kieren J. Mather, Axel Haupt, Panagiotis Flevaris, Ran Liao, Laiyi Chua, Charles Harris, Edward J. Pratt   +10 more
wiley   +1 more source